One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Serina Therapeutics, Inc.
SER · ASE · Healthcare · Biotechnology
Current price
$1.77
52-week range
$1.22 - $5.29
Market cap
$45.05M
Balance sheet
Healthy
-112.78x Concerning
Net cash $19.27M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Serina Therapeutics, Inc.
Serina Therapeutics develops new medicines, mainly for brain and nerve issues like Parkinson's disease, using a special technology. Their main money comes from developing these potential drugs and potentially from partnerships, which is important because it fuels the costly process of testing and getting these new treatments approved for people who need them.
How the company got here
Serina Therapeutics was founded in 2006 by J. Milton Harris and Michael Bentley, who had previously worked on PEG technology at Shearwater Polymers, a company that successfully developed drug delivery systems. Serina's journey began with a focus on developing a new generation of biopolymers, known as "POZ systems," designed to improve drug delivery. The company's early work centered on creating these "POZ" (polyoxazoline) polymers, which are safer and have a wide range of applications in pharmaceuticals. Serina Therapeutics is the only company globally that develops polyoxazoline polymers for pharmaceutical use. The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology.
What it actually does
Serina Therapeutics is a biotechnology company that focuses on developing new ways to deliver drugs, particularly for neurological diseases and pain. Their core innovation is the "POZ Platform™," a proprietary technology that uses special polymers to improve how drugs work in the body. This platform is designed to make drugs last longer, be more effective, and have fewer side effects, ultimately aiming to improve the patient's experience and quality of life. The company's technology can be applied to various types of medicines, including small molecules, RNA-based therapies, and antibody-drug conjugates.
SER-252 (POZ-apomorphine) for Parkinson's Disease
Serina's main focus is on developing SER-252, a drug candidate for advanced Parkinson's disease. SER-252 is a modified version of apomorphine, a known treatment for Parkinson's, that has been enhanced using Serina's POZ technology. The goal is to provide a more stable and sustained delivery of apomorphine, which could help manage Parkinson's symptoms more consistently and reduce the unpredictable "OFF" time that many patients experience. This new approach aims to allow patients to receive the medication through twice-weekly injections under the skin, rather than more invasive or frequent treatments. The company's Phase 1b clinical trial for SER-252 has shown promising safety and pharmacokinetic (how the body processes the drug) results, allowing the trial to proceed to higher doses.
POZ Technology for RNA Vaccines and Therapeutics
Beyond neurological diseases, Serina's POZ Platform™ is also being explored for use in RNA-based medicines, such as vaccines for infectious diseases. The company is developing "POZ-lipids," which are designed to be a non-immunogenic (meaning they don't trigger an unwanted immune response) alternative to the PEG-lipids currently used in lipid nanoparticles (LNPs). LNPs are crucial for delivering RNA-based therapies, like mRNA vaccines. By using their POZ technology, Serina aims to improve the delivery and performance of these RNA therapeutics, potentially making them safer and more effective. This area of development highlights the versatility of Serina's core technology.
What management is betting on now
Serina Therapeutics is primarily focused on advancing its lead drug candidate, SER-252, through clinical trials for Parkinson's disease. Management is betting that their proprietary POZ Platform™ technology can significantly improve the treatment of neurological disorders by enabling more consistent drug delivery and reducing side effects. The company is also exploring the application of its POZ technology in RNA-based therapeutics, including vaccines, and has entered into partnerships to further this development. Success in these areas could validate the broad potential of their drug delivery platform and lead to new therapeutic options for patients with significant unmet medical needs.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-2.96M
FY2024 Q4
$-4.59M
FY2025 Q1
$-4.32M
FY2025 Q2
$-3.80M
FY2025 Q3
$-3.86M
FY2025 Q4
$-6.03M
FY2026 Q1
$-4.59M
FY2026 Q2
$-6.71M
Revenue
$0.00
Net income
$-6.36M
Diluted EPS
-0.55
Operating cash flow
$-6.68M
Free cash flow
$-6.71M
Fetching…
Sources
Revenue
—
Net income
$-6.90M
Diluted EPS
-0.58
Operating cash flow
$-4.57M
Free cash flow
$-4.59M
Fetching…
Sources
Revenue
$0.00
Net income
$-3.34M
Diluted EPS
-0.31
Operating cash flow
$-6.03M
Free cash flow
$-6.03M
Fetching…
Sources
Revenue
$0.00
Net income
$-4.58M
Diluted EPS
-0.45
Operating cash flow
$-3.85M
Free cash flow
$-3.86M
Fetching…
Sources
Revenue
$130.00K
Net income
$-6.45M
Diluted EPS
-0.66
Operating cash flow
$-3.75M
Free cash flow
$-3.80M
Fetching…
Sources
Revenue
$0.00
Net income
$-4.81M
Diluted EPS
-0.49
Operating cash flow
$-4.32M
Free cash flow
$-4.32M
Fetching…
Sources
Revenue
$-14.00K
Net income
$-8.32M
Diluted EPS
1.23
Operating cash flow
$-4.59M
Free cash flow
$-4.59M
Fetching…
Sources
Revenue
$14.00K
Net income
$1.41M
Diluted EPS
0.13
Operating cash flow
$-2.96M
Free cash flow
$-2.96M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.77
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $19.3M - more cash than debt. Interest coverage -112.8x.
Net debt
$-19.27M
Interest coverage
-112.78x
Serina Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
SER
BASELINE
Serina Therapeutics, Inc.
Total debt $3.75M Interest coverage -112.78x This is the baseline the peer rows are being compared against.
Total debt $1.04M Interest coverage -15.06x Neither company has much profit cushion over interest right now.
Total debt $15.51M Interest coverage -16.10x Neither company has much profit cushion over interest right now.
Total debt $247.36M Interest coverage -8.77x Neither company has much profit cushion over interest right now.
Total debt $73.41M Interest coverage -15.10x Neither company has much profit cushion over interest right now.
Total debt $2.71B Interest coverage 84.52x This peer still has a real interest-payment cushion, while SER does not.
What you should know
The case for and against SER
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -207.9% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.69x
P/B
2.41x
P/S
—
EV/EBITDA
-1.00x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-207.9%
ROA
-92.3%
Health
Liquidity and balance-sheet strength
Debt / equity
0.20x
Current ratio
6.65x
Quick ratio
6.12x
Total debt
$3.75M
Total cash
$23.02M
Growth
How the business has been compounding
Revenue TTM
$130.00K
Revenue 5Y CAGR
-2.5%
EPS TTM
-1.87
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-21.14M
Free CF TTM
$-18.01M
FCF margin
-13,856.9%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—